The Science of Restoring Blood Flow: Autologous Stem Cell Therapy for Ischemic Disease
ACP-01 is derived from a patient’s own blood and evaluated in clinical research for ischemic conditions, including Heart Failure, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.
When blood flow is compromised and standard therapies have been exhausted, patients and physicians may begin looking toward investigational research to understand what is being studied next.
The Science of Restoring Blood Flow: Autologous Stem Cell Therapy for Ischemic Disease
ACP-01 is derived from a patient’s own blood and evaluated in clinical research for ischemic conditions, including Heart Failure, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.
When Blood Flow Is Compromised, Options Become Limited.
Many patients living with advanced peripheral arterial disease, critical limb ischemia, refractory angina, vascular cognitive impairment, chronic ischemic wounds, or persistent ischemic pain experience progressive symptoms despite prior medical or surgical interventions.
When conventional revascularization or symptom management strategies no longer provide meaningful improvement, uncertainty increases. Functional decline, discomfort, and reduced independence may follow.
Hemostemix is evaluating ACP-01 in clinical research to study whether improving microvascular circulation may influence ischemic tissue environments in selected patient populations.
Our Clinical Approach
ACP-01 is an investigational autologous stem cell therapy developed to support circulation in areas affected by ischemic disease. It is derived from a patient’s own blood and evaluated through structured clinical research.
Hemostemix has developed a proprietary cell processing platform designed to support reproducibility, quality control, and consistent preparation of ACP-01 within regulated research environments.
Conditions Studied in Clinical Research
ACP-01 has been evaluated in clinical research for select vascular and ischemic conditions. The following areas represent active investigation and research focus
Peripheral Arterial Disease
Peripheral arterial disease affects blood flow to the limbs and may lead to pain, non-healing wounds, or advanced tissue damage.
Learn More About Peripheral Arterial Disease →
Chronic Limb Threatening Ischemia
Chronic limb threatening ischemia represents an advanced stage of arterial disease marked by severe circulation impairment, rest pain, and risk of tissue loss.
Learn More About Chronic Limb Threatening Ischemia →
Information for Patients and Physicians
Select the pathway that aligns with your role to access detailed information.
Patients
If you are exploring clinical research options for advanced ischemic conditions, begin here to learn what to expect, eligibility considerations, and how evaluation works.
Physicians
If you are a referring or evaluating clinician seeking scientific background, study data, and research criteria, access physician-focused information here.
Clinical Research and Publications
ACP-01 has been evaluated in controlled clinical research across multiple ischemic indications. Hemostemix continues to analyze safety data and biological activity within defined study populations.
-
Angiogenic Precursor Cell Treatment of Critical Limb Ischemia Decreases Ulcer Size, Amputation and Death Rate: Re-Examination of phase II ACP NO-CLI Trial Data.
-
Autologous stem cell treatment for CLI patients with no revascularization options: ACP-01 4.5-year clinical update
-
Angiogenic Cell Precursors and Neural Cell Precursors in Service to the Brain-Computer Interface
-
Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages.
-
Safety and outcomes analysis: transcatheter implantation of autologous angiogenic cell precursors for the treatment of cardiomyopathy.
-
Treatment of Patients with Severe Angina Pectoris Using Intracoronarily Injected Autologous Blood-Borne Angiogenic Cell Precursors.
Clinical studies are conducted under established research protocols with defined inclusion criteria and ongoing regulatory compliance. ACP-01 remains investigational and is not approved by the U.S. FDA.
Our Origin
Roger Bergersen was the principal founder of TheraVitae Inc., which later became Hemostemix Inc.
In 2005, after being diagnosed with advanced heart disease, Mr. Bergersen sought investigational autologous cell therapy outside the United States. The procedure involved isolating angiogenic precursor cells from his own blood and administering them in an effort to address ischemic cardiac tissue.
Following that experience, he became committed to supporting structured clinical research in autologous angiogenic cell therapy. This commitment ultimately led to the founding of Hemostemix and the formal clinical development of ACP-01.
Since that time, Hemostemix has conducted multiple clinical studies evaluating ACP-01 in ischemic conditions including critical limb ischemia, ischemic cardiomyopathy, refractory angina, and vascular-related cognitive impairment. The company continues to advance disciplined clinical research within established regulatory frameworks.
ACP-01 remains investigational and is not approved by the U.S. Food and Drug Administration.
Mr. Bergersen remained engaged in the company’s development efforts until his passing in February 2020.
Request A Clinical Research Consultation
If you have been diagnosed with an advanced vascular or ischemic condition and are exploring investigational clinical research options, you may request a consultation to determine whether further review is appropriate.
Disclaimer
This notice is provided in accordance with Florida law. One or more physicians referenced may perform stem cell therapies that have not been approved by the United States Food and Drug Administration. Patients are encouraged to consult with their primary care provider before undergoing any stem cell therapy.